The BCL2L11 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the BCL2L11 gene in the A-549 human lung adenocarcinoma cell line. This model eliminates expression of the pro-apoptotic BH3-only protein BIM, providing a loss-of-function tool to study BIM-dependent apoptosis and its role in cancer cell survival and drug sensitivity. The polyclonal pool retains genetic heterogeneity while uniformly lacking functional BIM, suitable for pooled functional assays and screening applications.
The A-549 cell line is derived from the lung adenocarcinoma of a 58-year-old Caucasian male. It displays epithelial morphology and is a widely used in vitro model for non-small cell lung cancer (NSCLC). A-549 cells are well-characterized for their apoptotic regulation and drug response profiles, making them an appropriate background to explore the Bcl-2 family network and mitochondrial apoptosis pathways in lung adenocarcinoma.
BCL2L11 encodes BIM, a BH3-only protein that initiates the intrinsic apoptotic pathway. BIM binds and neutralizes anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xL, Mcl-1, Bcl-w, A1), freeing BAX and BAK to oligomerize on the outer mitochondrial membrane, leading to cytochrome c release and Apaf-1/caspase-9 apoptosome formation, which activates caspase-3 and -7. BIM is transcriptionally regulated by FOXO3a and post-translationally by JNK and ERK kinases, and is induced by stimuli such as IL-3 withdrawal and glucocorticoids. Additionally, BIM interacts with Beclin-1, linking apoptosis to autophagy. Thus, BIM integrates stress signals to control cell death.
In A-549 cells, BCL2L11 knockout abrogates a critical pro-apoptotic sensor, enabling dissection of how lung adenocarcinoma cells evade apoptosis. BIM is implicated in mediating the cytotoxic effects of targeted therapies, including EGFR inhibitors and BH3 mimetics. Consequently, this knockout model is valuable for investigating resistance mechanisms and identifying alternative apoptotic pathways in NSCLC.
These polyclonal knockout cells support diverse research applications, including apoptosis pathway analysis, drug resistance studies, and BH3 mimetic screening. Typical validation experiments utilize Annexin V assays, caspase-3/7 activity measurement, JC-1 mitochondrial potential analysis, and co-immunoprecipitation of BIM with anti-apoptotic partners. Western blotting for BIM, cleaved caspase-9, and cytochrome c confirms pathway activity. For further information or custom services, please contact Ascent Research.
